News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
It’s an AB-rated generic therapeutic version of Durezol
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
Subscribe To Our Newsletter & Stay Updated
